Evidence map›Paper›PMID 37150255›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2023

Mosaic Chromosomal Alterations Are Associated With Increased Lung Cancer Risk: Insight From the INTEGRAL-ILCCO Cohort Analysis.

Chao Cheng, Wei Hong, Yafang Li, Xiangjun Xiao, James McKay, Younghun Han, Jinyoung Byun, Bo Peng, Demetrios Albanes, Stephen Lam and 37 more

Abstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Chao ChengInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Wei HongInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.
Yafang LiInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Xiangjun XiaoInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas.
James McKaySection of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.
Younghun HanInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Jinyoung ByunInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Bo PengInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Demetrios AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stephen LamDepartment of Integrative Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Adonina TardonPublic Health Department, University of Oviedo, ISPA and CIBERESP, Asturias, Spain.
Chu ChenProgram in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Stig E BojesenDepartment of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Maria T LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mattias JohanssonSection of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.
Angela RischThoraxklinik at University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; University of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
H-Erich WichmannInstitute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Gad RennertClalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Susanne ArnoldUniversity of Kentucky, Markey Cancer Center, Lexington, Kentucky.
Gary GoodmanSwedish Cancer Institute, Seattle, Washington.
John K FieldDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Michael P A DaviesDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Sanjay S SheteDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Loic Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Geoffrey LiuUniversity Health Network- The Princess Margaret Cancer Centre, Toronto, California.
Rayjean J HungLuenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Angeline S AndrewDepartment of Epidemiology, Dartmouth College, Hanover, New Hampshire; Department of Community and Family Medicine, Dartmouth College, Hanover, New Hampshire.
Lambertus A KiemeneyRadboud University Medical Center, Nijmegen, The Netherlands.
Meng ZhuDepartment of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Hongbing ShenDepartment of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Shan ZienolddinyNational Institute of Occupational Health, Oslo, Norway.
Kjell GrankvistDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Mikael JohanssonDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Angela CoxAcademic Unit of Clinical Oncology University of Sheffield, Weston Park Hospital, Whitham Road, Sheffield, United Kingdom.
Yun-Chul HongDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jian-Min YuanUniversity of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania.
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Melinda C AldrichDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Paul BrennanSection of Genetics, International Agency for Research on Cancer, WHO, Lyon, France.
Yong LiInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Olga GorlovaInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Ivan GorlovInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. Electronic address: chris.amos@bcm.edu.
INTEGRAL-ILCCO Lung Cancer Consortium

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, Rayjean J. Hung · 2017 to 2026
$23.7M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
THE SINGAPORE COHORT STUDY OF DIET AND CANCERR01CA080205 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YUAN, JIAN-MIN · 1999 to 2009
$5.3M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
An innovative integrated computational framework using gene signatures for patient stratificationR01CA269764 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CHAO CHENG · 2023 to 2026
$1.8M
Computational Identification of new candidate drugs for lung cancer treatmentR21CA227996 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CHENG, CHAO, ONEGA, TRACY · 2019 to 2020
$397k
The Singapore Chinese Health StudyU01CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2019 to 2019
$150k
NCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA080205NCI NIH HHS R01 CA144034NCI NIH HHS R01 CA269764NCI NIH HHS R21 CA227996NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA182876NCI NIH HHS U19 CA203654NCI NIH HHS UM1 CA182876World Health Organization 001
6 · The paper itself

Abstract

introductionMosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared with CH-related somatic mutations. A few recent studies indicated their potential link with nonhematological cancers, especially lung cancer.

methodsIn this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with 18,221 lung cancer cases and 14,825 cancer-free controls.

resultsWe identified a comprehensive list of autosomal mCAs, ChrX mCAs, and mosaic ChrY (mChrY) losses from these samples. Autosomal mCAs were detected in 4.3% of subjects, in addition to ChrX mCAs in 3.6% of females and mChrY losses in 9.6% of males. Multivariable logistic regression analysis indicated that the presence of autosomal mCAs in white blood cells was associated with an increased lung cancer risk after adjusting for key confounding factors, including age, sex, smoking status, and race. This association was mainly driven by a specific type of mCAs: copy-neutral loss of heterozygosity on autosomal chromosomes. The association between autosome copy-neutral loss of heterozygosity and increased risk of lung cancer was further confirmed in two major histologic subtypes, lung adenocarcinoma and squamous cell carcinoma. In addition, we observed a significant increase of ChrX mCAs and mChrY losses in smokers compared with nonsmokers and racial differences in certain types of mCA events.

conclusionsOur study established a link between mCAs in white blood cells and increased risk of lung cancer.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsChromosome AberrationsCohort StudiesFemaleHumansMaleSmokingClonal hematopoiesisLoss of heterozygosityLung cancer riskMosaic chromosomal alterations

Identifiers

PMID37150255
PMCPMC10435278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.